Altre lingue Agios Pharmaceuticals, Inc.

Azioni

AGIO

US00847X1046

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
31,67 ^USD	0,00%		+7,61%	+42,21%

16/02	AGIOS PHARMACEUTICALS, INC. : prospettiva positiva di RBC Capital Markets	ZM
15/02	Agios Pharmaceuticals, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024	18/04
Agios Publishes 2024 Environmental, Social and Governance Report	10/04
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report	09/04
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	06/03
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	05/03
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024	22/02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	15/02
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	15/02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Servier replonge dans le rouge en raison du dossier Mediator	07/02
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024	02/02
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	09/01
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	03/01
Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results	03/01
Agios' blood disorder drug meets goals of late-stage study	03/01
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Agios Pharmaceuticals, Inc.

Azioni

AGIO

US00847X1046

Altre lingue

Filtri